In our most recent survey of EDC users, respondents indicated they are currently using 2.4 EDC systems on average to conduct their companies’ clinical trials. Respondents anticipate using 2.9 systems in the future. These numbers are down from the 3.2 systems (current) and 4.1 systems (projected) reported in 2018. Variation in system use exists when segmenting by R&D spend, where the biggest projected growth is anticipated for the smallest and largest sponsors. However, no segment predicted using an additional EDC system on average, as would be indicated by a full point increase from the current use.

Originally published in Life Science Leader.

View File